Available data from NSCLC showed that plasma/serum Ang2 is elevated at POD1, POD3, POD7, and POD30 compared to the preoperative levels.[6, 7]Based on the clinical practice that adjuvant therapy usually starts 4 to 6 weeks after surgery and that the bevacizumab therapy is recommended to start 4 to 8 weeks after surgery,[20] we extended the plasma sampling to 8 weeks after surgery. The gene discussed is ANGPT2; the disease is non-small cell lung carcinoma.